Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: Rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

European Journal of Heart Failure

Volumn 15, Issue 9, 2013, Pages 1062-1073

  McMurray, John J V ^a   Packer, Milton ^b   Desai, Akshay S ^c   Gong, Jim ^d   Lefkowitz, Martin P ^d   Rizkala, Adel R ^d   Rouleau, Jean ^e   Shi, Victor C ^d   Solomon, Scott D ^c   Swedberg, Karl ^f   Zile, Michael R ^g  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e MONTREAL HEART INSTITUTE   (Canada)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

ACE inhibitor; Angiotensin receptor blocker; Angiotensin receptor neprilysin inhibitor; Chronic heart failure; LCZ696; Natriuretic peptides; Neprilysin; Neutral endopeptidase; Renin angiotensin

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; MOEXIPRIL; OLMESARTAN; PERINDOPRIL; POTASSIUM; QUINAPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; ZOFENOPRIL;

CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DEATH; DRUG DOSE TITRATION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTOLIC HEART FAILURE;

ACE INHIBITOR; ANGIOTENSIN RECEPTOR BLOCKER; ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR; CHRONIC HEART FAILURE; LCZ696; NATRIURETIC PEPTIDES; NEPRILYSIN; NEUTRAL ENDOPEPTIDASE; RENIN-ANGIOTENSIN;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ENALAPRIL; HEART FAILURE, SYSTOLIC; HOSPITALIZATION; HUMANS; MORBIDITY; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SURVIVAL RATE; TETRAZOLES;

EID: 84880206504     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft052     Document Type: Review

References (46)

1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-254.
2. Swedberg K. Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. Eur J Heart Fail 2000;2:229-233. (Pubitemid 30670718)
3. Packer M. Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease. Eur Heart J 1996;17 (Suppl B):21-23. (Pubitemid 26136856)
4. McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail 2011;13:929-936.
5. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3: 351-357. (Pubitemid 32895844)
6. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natri-uretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94. (Pubitemid 11184926)
7. Lee ME Jr., Miller WL, Edwards BS, Burnett JC Jr. Role of endogenous atrial natri-uretic factor in acute congestive heart failure. J Clin Invest 1989;84:1962-1926.
8. Wada A, Tsutamoto T, Matsuda Y, Kinoshita M. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 1994;89:2232-2240. (Pubitemid 24142803)
9. Brandt RR Jr., Redfield MM, Aarhus LL, Lewicki JA, Burnett JC Jr. Clearance receptor-mediated control of atrial natriuretic factor in experimental congestive heart failure. Am J Physiol 1994;266:R936-R943.
10. Mangiafico S Jr., Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 2012;in press.
11. McMurray J, Struthers AD. Significance of atrial natriuretic factor in chronic heart failure. Br J Hosp Med 1988;40:55-57.
12. Northridge DB, Jardine AG, Alabaster CT, Barclay PL, Connell JM, Dargie HJ, Dilly SG, Findlay IN, Lever AF, Samuels GM. Effects of UK 69 578: a novel atrio-peptidase inhibitor. Lancet 1989;2:591-593. (Pubitemid 19216209)
13. Münzel T, Kurz S, Holtz J, Busse R, Steinhauer H, Just H, Drexler H. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 1992;86: 1089-1098.
14. Newby DE, McDonagh T, Currie PF, Northridge DB, Boon NA, Dargie HJ. Can-doxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Eur Heart J 1998;19:1808-1813. (Pubitemid 28556650)
15. McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vaso-peptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000;36: 479-486. (Pubitemid 30624011)
16. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-620. (Pubitemid 30627587)
17. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-926. (Pubitemid 34925324)
18. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103-111. (Pubitemid 38125125)
19. Fryer RM, Segreti J, Banfor PN, Widomski DL, Backes BJ, Lin CW, Ballaron SJ, Cox BF, Trevillyan JM, Reinhart GA, von Geldern TW. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008;153:947-955. (Pubitemid 351328937)
20. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprily-sin inhibitor (ARNi). J Clin Pharmacol 2010;50:401-414.
21. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255-1266.
22. Hegde LG, Yu C, Renner T, Thibodeaux H, Armstrong SR, Park T, Cheruvu M, Olsufka R, Sandvik ER, Lane CE, Budman J, Hill CM, Klein U, Hegde SS. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol 2011;57:495-504.
23. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245-1255. (Pubitemid 30206900)
24. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
25. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771. (Pubitemid 37093916)
26. Prasad PP, Yeh C-M, Gurrieri P, Glazer R, McLeod J. 2002. Pharmacokinetics of multiple doses of valsartan in patients with heart failure. J Cardiovasc Pharmacol; 40:801-807. (Pubitemid 36109298)
27. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824-839.
28. Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH, Dunselman P, Hjalmarson A, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F; CORONA Study Group. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009;11:281-291.
29. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
30. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-1435.
31. Effect of enalapril on mortality and the development of heart failure in asymptom. atic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685-691.
32. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic con-gestive heart failure. N Engl J Med 1991;325:303-310.
33. Clinical outcome with enalapril in symptomatic chronic heart failure;a dose com. parison. The NETWORK Investigators. Eur Heart J 1998;19:481-489.
34. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, Karidis K, Tirologos A, Zobolos S, Pirgakis V, Anthopoulos L, Sideris D, Stamatelopoulos SF, Moulopoulos SD. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril:a multicenter study. High Enalapril Dose Study Group. J Am Coll Cardiol 2000;36:2090-2095.
35. Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt PJaarsma W, Riegger G, Rydén L, Scherhag A, Soler-Soler J, Remme WJ; CARMEN investigators '. and co-ordinators. Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). EurJ Heart Fail 2004;6:467-475. (Pubitemid 38746591)
36. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P; CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:2426-2435. (Pubitemid 41504492)
37. Messner Pellenc P, Rudnicki A, Leclercq F, Grolleau R. Enalapril in the treatment of mild-to-moderate heart failure in general medical practice: a prospective and multicentre study concerning 17, 546 patients. Acta Cardiol 1995;50:187-201.
38. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675. (Pubitemid 33126822)
39. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906. (Pubitemid 37409706)
40. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380: 1387-1395.
41. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885.
42. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
43. Lafferty HM, Gunning M, Silva P, Zimmerman MB, Brenner BM, Anderson S. Enke-phalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary sodium excretion in rats with reduced renal mass. Circ Res 1989;65:640-646. (Pubitemid 19226440)
44. van der Zander K, Houben AJ, Hofstra L, Kroon AA, de Leeuw PW. Hemodynam-ic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am J Physiol Heart Circ Physiol 2003; 285:H1206-H1212. (Pubitemid 37048178)
45. Jungmann E, Konzok C, Höll E, Fassbinder W, Schöffling K. Effect of human atrial natriuretic peptide on blood glucose concentrations and hormone stimulation during insulin-induced hypoglycaemia in healthy man. Eur J Clin Pharmacol 1989; 36:593-597. (Pubitemid 19175871)
46. Pfister R, Sharp S, Luben R, Welsh P, Barroso I, Salomaa V, Meirhaeghe A, Khaw KT, Sattar N, Langenberg C, Wareham NJ. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes:evidence of causal association from population studies. PLoS Med 2011;8:e1001112.